Full-Time

Web Strategy & Operations Associate

Updated on 8/22/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's, Master's, PhD, Associate's

Category
Business & Strategy (1)
Required Skills
Agile
ServiceNow
SEO
JIRA
Risk Management
Confluence
Web Development
HTML/CSS
Google Analytics

Get referred to Amgen

See people who can refer or advise you

Requirements
  • Doctorate degree, or a master's degree and 2 years of digital or web project management experience, or a bachelor's degree and 4 years of digital or web project management experience, or an associate's degree and 10 years of digital or web project management experience, or a high school diploma/GED and 12 years of digital or web project management experience.
  • Knowledge of Agile methodologies, preferably Scaled Agile Framework (SAFe).
  • Proficiency with program or project management tools such as JIRA, ServiceNow, Confluence, and Google Analytics.
  • Experience managing end-to-end digital and website lifecycle projects in fast-paced, multi-stakeholder environments.
  • Experience managing complex, cross-country, and high-impact initiatives.
  • Experience operating in regulated industries, preferably pharmaceuticals, with an understanding of compliance requirements.
  • Experience developing detailed project documentation and translating business requirements into technical specifications.
  • Proficiency in web analytics, search engine optimization, and user experience/user interface principles.
  • Ability to work across time zones when required.
Responsibilities
  • Support the coordination and execution of cross-functional web projects, including alignment on timelines, resources, and budgets for website enhancements and optimization initiatives.
  • Partner with program leads to track progress, maintain alignment across initiatives, identify potential risks, and escalate risks as needed.
  • Support quarterly portfolio intake and prioritization across web initiatives with Technology and business stakeholders.
  • Operationalize governance frameworks to evaluate demand, clarify project-level requirements, assess cross-project dependencies, and align delivery.
  • Assist with day-to-day coordination across content, design, development, search engine optimization, analytics, project owners, and platform stakeholders.
  • Monitor delivery progress, governance adherence, documentation standards, cross-project risks, issues, and change impacts through launch and hypercare.
  • Track and report key performance indicators by analyzing web traffic, user behavior, and search engine optimization metrics.
  • Conduct functional testing and ensure adherence to Agile web development processes, industry best practices, and quality standards.
  • Support retrospectives and identify opportunities to improve efficiency and speed to market.
  • Support adoption of governance frameworks, templates, and delivery processes.
  • Assess and optimize the web portfolio to align with business priorities, resource capacity, and long-term digital strategy.
  • Ensure compliance with regulatory, legal, and brand standards across web initiatives and embed risk management into project governance.
  • Support regional leads with website operational activities, including access management, platform configuration, and risk assessments.
Desired Qualifications
  • Three or more years of experience managing end-to-end digital and website lifecycle projects.
  • Experience managing website roadmaps and continuous improvement initiatives.
  • Experience negotiating priorities, managing expectations, and building relationships across cross-functional teams and external partners.
  • Familiarity with web accessibility standards such as Web Content Accessibility Guidelines (WCAG).
  • Familiarity with privacy regulations such as the General Data Protection Regulation (GDPR) and California Consumer Privacy Act (CCPA).
  • Familiarity with web technologies such as HTML and CSS.
  • Proficiency with digital marketing tools.
  • Ability to interpret data and drive actionable insights.
  • Experience with user experience/user interface principles.
  • Experience developing productive relationships with vendors.
  • Experience working in the pharmaceutical industry.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $10.1 billion, up 10%, and guidance rose to $39.4 billion.
  • Repatha, Evenity, and Uplizna surged 37%, 38%, and 90% in Q2 2026.
  • Amgen presented Repatha VESALIUS-CV data for ESC August 2026, expanding cardiovascular adoption.

What critics are saying

  • FDA proposed withdrawing Tavneos on April 27, 2026; EMA echoed revocation on June 26.
  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy franchise.
  • Harbour BioMed won a June 2026 willful patent verdict; MariTide failure would crush growth.

What makes Amgen unique

  • Amgen’s portfolio spans cardiovascular, bone, immunology, oncology, and biosimilars.
  • MariTide targets monthly or less frequent obesity dosing, unlike weekly GLP-1 rivals.
  • Amgen runs seven research labs plus Hyderabad’s 2027 science and innovation center.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.